

# **The Role of Misfolded Proteins in Neurodegenerative Diseases**

*An Essay*

Submitted for Partial Fulfillment of Master Degree  
*in Neuropsychiatry*

*By*

**Marwa Mohamed moawed**

M.B.,B.Ch.

Faculty of Medicine- Benha University

*Under supervision of*

**Prof. Dr/ Magd fouad Zakaria**

*Professor of Neurology and Psychiatry*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr/ Nagia Aly Fahmy**

*Professor of Neurology and Psychiatry*

*Faculty of Medicine, Ain Shams University*

**Dr/ Mohamed Khaled Elewa**

*Lecturer of Neurology and Psychiatry*

*Faculty of Medicine, Ain Shams University*

**Faculty of Medicine**

**Ain shams university**

**2014**



قَالُوا سُبْحَانَكَ

لَا عِلْمَ لَنَا

إِلَّا مَا عَلَّمْنَا

إِنَّكَ أَنْتَ

الْعَلِيمُ الْحَكِيمُ

ا. صرق الله العظيم

سورة البقرة (الآية ٣٢)

## Acknowledgment

*First, I would like to thank Allah the merciful and compassionate for making all this work possible and for granting me with the best teachers, family, friends, and colleagues that many people would wish and dream of having.*

*I am honored to have Prof. Dr. Magd Fouad Zakaria, Professor of Neurology, Faculty of Medicine, Ain Shams University, as a supervisor of this work. I am greatly indebted to his for his kind guidance and patience.*

*I am deeply thankful to Prof. Dr. Magia Aly Fahmy, Professor of Neurology, Faculty of Medicine, Ain Shams University, for her great help and effort to make this work possible. I was honored to work with her.*

*Words can not express my deep gratitude and sincere appreciation to Dr. Mohamed Khaled Elewa, Lecturer of Neurology, Faculty of Medicine, Ain Shams University, who assisted me in most of the work. I am greatly grateful for his generous help, kind advice, and kind guidance.*

*Furthermore I would like to convey my special thanks to all my staff members, my colleagues and last but not least my wonderful family.*

# Contents

	<b>Page</b>
List of Tables .....	<b>I</b>
List of Figures .....	<b>II</b>
List of Abbreviations .....	<b>III</b>
Introduction.....	<b>1</b>
Aim of the Work .....	<b>4</b>
Chapter 1: Proteins: structure and folding process .....	<b>5</b>
Chapter 2: Protein misfolding: aggregation and amyloid formation .....	<b>21</b>
Chapter 3: Proteins misfolding in neurodegenerative diseases: Cause or Response? .....	<b>32</b>
Chapter 4: Diagnostic and Therapeutic approaches to protein misfolding neuro- degenerative diseases .....	<b>61</b>
Discussion .....	<b>73</b>
Conclusions and Recommendations .....	<b>80</b>
Summary .....	<b>83</b>
References .....	<b>88</b>
Arabic Summary .....	<b>—</b>

# **List of Tables**

***Table No.***

***Page No.***

**Table (1):** Summary of protein-modifying conditions  
and their affected proteins or peptides .....23

**Table (2):** Proteins susceptible to misfolding and their  
associated diseases .....35

# List of Figures

<b><i>Figure No.</i></b>	<b><i>Page No.</i></b>
<b>Fig (1):</b> Models alpha-helix and beta sheets .....	8
<b>Fig (2):</b> Schematic representation of the structural component of proteins .....	9
<b>Fig (3):</b> Schematic energy landscape for protein folding .....	11
<b>Fig (4):</b> Energy state of protein folding under physiological and misfolding conditions .....	12
<b>Fig (5):</b> Molecular chaperones regulate several important cellular processes .....	17
<b>Fig (6):</b> Protein misfolding and aggregation .....	24
<b>Fig (7):</b> Composition of amyloid cross- $\beta$ structure .....	27
<b>Fig (8):</b> Microscopic image of brain tissue form an Alzheimer disease .....	39
<b>Fig (9):</b> Structure of amyloid fibrils in Parkinson's disease .....	46
<b>Fig (10):</b> Induction of the heat shock response .....	72

## List of Abbreviations

<b><math>\alpha</math> .....</b>	Alpha
<b><math>\beta</math> .....</b>	Beta
<b><math>\gamma</math> .....</b>	Gamma
<b><math>\alpha</math>-syn .....</b>	$\alpha$ -synculein
<b>17AAG.....</b>	17-allylamino-17-demethoxy geldanamycin
<b>A<math>\beta</math>.....</b>	Beta-amyloid
<b>AA.....</b>	Amino acid
<b>ABri .....</b>	British amyloid peptide
<b>AD .....</b>	Alzheimer's disease
<b>ADan.....</b>	Danish amyloid peptide
<b>AIF.....</b>	Apoptosis inducing factor
<b>ALS.....</b>	Amyotrophic lateral sclerosis
<b>ApoE.....</b>	Apolipoprotein E
<b>APP .....</b>	Amyloid precursor protein
<b>AR.....</b>	Androgen receptor
<b>ATP.....</b>	Adenosine triphosphatases
<b>BACE.....</b>	Beta secretase
<b>Ca<sup>+2</sup> .....</b>	Ionized Calcium
<b>Cdk .....</b>	Cyclin-dependent protein kinase
<b>CFTR.....</b>	Cystic fibrosis conductance regulator

<b>CIDNP .....</b>	Chemically induced nuclear polarization
<b>CJD .....</b>	Creutzfeld-Jacob disease
<b>DMSO.....</b>	Dimethyl sulfoxide
<b>DNA .....</b>	Deoxyribonucleic acid
<b>DRPLA.....</b>	Dentatorubral pallidolysian atrophy
<b>ER .....</b>	Endoplasmic reticulum
<b>ERAD .....</b>	Endoplasmic-reticulum associated degradation
<b>ERK .....</b>	Extracellular regulated kinase
<b>FAD .....</b>	Familial Alzheimer's disease
<b>FBD.....</b>	Familial British Dementia
<b>FDD .....</b>	Familial Danish Dementia
<b>FFI .....</b>	Fatal familial insomnia
<b>FTDP-17.....</b>	Frontotemporal dementia with Parkinsonism-17
<b>GPI.....</b>	Glycophosphatidylinositol
<b>GRP .....</b>	Glucose-regulated protein
<b>GSK .....</b>	Glycogen synthase kinase
<b>GSS .....</b>	Gerstmann-straussler-scheinker syndrome
<b>HD.....</b>	Huntington's disease
<b>HDX.....</b>	Hydrogen/deuterium exchange
<b>HIBM.....</b>	Hereditary inclusion body myopathy
<b>HRP .....</b>	Heat shock responsive protein
<b>HSC 70 .....</b>	Heat shock cognate 70

#### IV



<b>HSEs .....</b>	Heat shock elements
<b>HSF1 .....</b>	Heat shock transcription factor 1
<b>HSP .....</b>	Heat shock protein
<b>HSR .....</b>	Heat shock response
<b>Ig .....</b>	Immunoglobulin
<b>JNK.....</b>	c-jun N-terminal kinase
<b>KDa.....</b>	Kilo Dalton
<b>LAMP.....</b>	Lysosomal associated membrane protein
<b>LDL .....</b>	Low density lipoprotein
<b>MAP.....</b>	Mitogen activated protein
<b>MAPK .....</b>	Mitogen-activated protein kinase
<b>MSA.....</b>	Multiple system atrophy
<b>NAC .....</b>	Non A beta component
<b>NFT's.....</b>	Neurofibrillary tangles
<b>NMDA .....</b>	N-methyl-D-aspartate
<b>NMR .....</b>	Nuclear magnetic resonance
<b>NO .....</b>	Nitric oxide
<b>NSAID .....</b>	Non-steroidal-anti-inflammatory drugs
<b>PABP2 .....</b>	Poly (A) binding protein 2
<b>PD .....</b>	Parkinson's disease
<b>PK .....</b>	Protein kinase-k
<b>PrDs .....</b>	Prion related disorders

<b>PrP<sup>c</sup> .....</b>	Cellular prion protein
<b>PrP<sup>sc</sup> .....</b>	Prion protein scrapie
<b>PS .....</b>	Presenilin
<b>RNA .....</b>	Ribonucleic acid
<b>ROS .....</b>	Reactive oxygen species
<b>SBMA .....</b>	Spinal & bullar muscular atrophy
<b>SCA.....</b>	Spinocerebellar ataxias
<b>sHSPs.....</b>	Small heat shock proteins
<b>SIBM .....</b>	Sporadic inclusion body myositis
<b>SOD .....</b>	Superoxide dismutases
<b>UPR .....</b>	Unfolded protein response
<b>vCJD.....</b>	Variant Creutzfeld-Jakob disease

## **Introduction**

A growing numbers of neurodegenerative diseases are associated nowadays with the expression of misfolded proteins. As known that protein molecules are responsible for almost all biological functions in the cell. In order to fulfill their various biological roles, these chain-like molecules must fold into precise three-dimensional shapes (*Hartl, 2010*).

The order of the amino acids determines the *primary* structure of the protein by creating a unique polypeptide chain, which is relatively flexible. Protein folding is the process by which the newly synthesized protein molecule folds into its unique, three- dimensional structure as polypeptides can fold into three *secondary* elements: the alpha-helix and the beta-sheet, which determine the three-dimensional structure of the protein, and the random coil. The *tertiary* structure refers to the distribution of the alpha-helices, beta-sheets and random coils in the protein, where in these elements are folded into a compact conformation stabilized by hydrogen bonds or ionic interaction. To become functional, the protein has to be packed into its particular *native* conformation. In the cell, a variety of proteins named chaperones assist the newly synthesized

polypeptide to attain its native conformation (*Bryngelson et al., 1995; Herczenik and Gebbink, 2008*).

Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. Genetic mutations are the main cause for protein misfolding in rare families, but the majority of patients have sporadic forms possibly related to environmental factors that results in the unfolding of the proteins which have a tendency to aggregate. Recent studies suggest that generation of excessive nitric oxide (NO) and reactive oxygen species (ROS), in part due to overactivity of the N-methyl-D-aspartate (NMDA) - subtype of glutamate receptor, can mediate protein misfolding in the absence of genetic predisposition (*Nelson et al., 2005; Nakamura and Lipton, 2009*).

Protein aggregation can result in several neurodegenerative diseases such as: Alzheimer's disease (deposits of amyloid beta and tau), Parkinson's disease (deposits of alpha synculein), Myotonic Dystrophies, Inclusion-Body Myositis and Prion related Disorders (PrDs) which also known as Transmissible spongiform encephalopathies (deposits of prion protein) (*Matus et al., 2011*).

Recent findings provide new concepts for inhibition of protein aggregation and its proinflammatory and cytotoxic effects. The main approaches fall into the following categories: Small compounds that inhibit aggregation; such as 2,4-dinitrophenol, di- and tri substituted aromatic molecules, Immunotherapy (antibody therapy and vaccination), and Compounds that interfere with amyloid-cell or amyloid-protein interactions (*Verdier and Penke, 2006; Herczenik and Gebbink, 2008*).

Some recent studies proposed that molecular chaperones are neuroprotective because of their ability to modulate the earliest aberrant protein interactions as they may convert toxic conformations of misfolded proteins to nontoxic forms that can be tolerated by cells, also they prevent the formation of toxic pre-fibrillar intermediates, or accelerate their conversion to nontoxic amorphous aggregates that can be turned over more easily by the proteolytic machinery (*Muchowski et al., 2002*).

## **Aim of the Work**

### **To Review:**

- 1- Why and how proteins are misfolded.
- 2- The role of misfolded proteins in pathogenesis of neurodegenerative diseases.
- 3- Recent diagnostic procedures and therapies for neurodegenerative diseases.
- 4- Future prospect of neurodegenerative disease' therapy.

**For** better understanding, diagnosis and therapy of neurodegenerative diseases.

## ***Chapter (1):***

# **Proteins: Structure and Folding Process**

Proteins are essential elements for life. They are building blocks of all organisms and the operators of cellular functions. Humans produce a repertoire of at least 30,000 different proteins, each with a different role. The function of a protein can only be interpreted from its structure. The nervous system is a network of cells, and the peculiar functional properties of these cells can be derived from the properties and interactions of their proteins. Proteins are involved in all stages of neural activity. Those embedded wholly or partly in membranes regulate the transport of ions and molecules as a means of signal exchange with other cells and the external medium. Some of them have enzymatic functions to catalyze the chemical processes essential for function (*Makhatadze and Privalov, 1995; Baldwin, 2007*).

## **The structure of proteins**

Proteins are molecules composed of an amino acid chain, in which each amino acid is connected to the next one by a peptide bond. Proteins are very diverse and vary in size from small peptides to large multimers. The variation